Antimalarial drug resistance.

Malaria, the most prevalent and most pernicious parasitic disease of humans, is estimated to kill between one and two million people, mainly children, each year. Resistance has emerged to all classes of antimalarial drugs except the artemisinins and is responsible for a recent increase in malaria-related mortality, particularly in Africa. The de novo emergence of resistance can be prevented by the use of antimalarial drug combinations. Artemisinin-derivative combinations are particularly effective, since they act rapidly and are well tolerated and highly effective. Widespread use of these drugs could roll back malaria.

[1]  N. White,et al.  Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[2]  N. White,et al.  Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[3]  B. Greenwood,et al.  Mass administrations of antimalarial drugs. , 2003, Trends in parasitology.

[4]  M. Kolczak,et al.  The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya , 2003, AIDS.

[5]  W. Peters Chemotherapy and drug resistance in malaria. 2nd edition. Vols 1 and 2continued. , 1987 .

[6]  S. Siziya,et al.  Association of HIV infection with the development of severe and complicated malaria cases at a rural hospital in Zimbabwe. , 2000, The Central African journal of medicine.

[7]  D E EYLES,et al.  Infectivity to mosquitoes of Plasmodium falciparum as related to gametocyte density and duration of infection. , 1955, The American journal of tropical medicine and hygiene.

[8]  T. Smith,et al.  Attributable fraction estimates and case definitions for malaria in endemic areas. , 1994, Statistics in medicine.

[9]  J. Verdrager Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. , 1986, The Journal of tropical medicine and hygiene.

[10]  S. Krishna,et al.  Artemisinins target the SERCA of Plasmodium falciparum , 2003, Nature.

[11]  R. Price,et al.  Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  K. Marsh Malaria disaster in Africa , 1998, The Lancet.

[13]  X. Su,et al.  Complex Polymorphisms in an ∼330 kDa Protein Are Linked to Chloroquine-Resistant P. falciparum in Southeast Asia and Africa , 1997, Cell.

[14]  L. Aarons,et al.  Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection , 2002, Parasitology.

[15]  N. White,et al.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.

[16]  B. Levin,et al.  The population dynamics of antimicrobial chemotherapy , 1997, Antimicrobial agents and chemotherapy.

[17]  N. French,et al.  Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence , 2003, The Pediatric infectious disease journal.

[18]  N. White,et al.  The de novo selection of drug–resistant malaria parasites , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[19]  H. Webster,et al.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.

[20]  C. Shulman,et al.  Importance and prevention of malaria in pregnancy. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[21]  X. Su,et al.  Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. , 1997, Cell.

[22]  N. White,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine , 1999 .

[23]  R. Douglas,et al.  Plasmodium species (malaria). , 1990 .

[24]  J. Meuwissen,et al.  Feeding behaviour and sporozoite ejection by infected Anopheles stephensi. , 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[25]  Richard N. Price,et al.  Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study , 2000, The Lancet.

[26]  Q. Cheng,et al.  Mutations in Plasmodium falciparumCytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site , 2000, Antimicrobial Agents and Chemotherapy.

[27]  N. White The assessment of antimalarial drug efficacy. , 2002, Trends in parasitology.

[28]  D. Warhurst,et al.  The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[29]  S. Kyes,et al.  Antigenic variation at the infected red cell surface in malaria. , 2001, Annual review of microbiology.

[30]  N. White,et al.  Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. , 1996, Blood.

[31]  W. Watkins,et al.  Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[32]  N. White,et al.  The evolution of drug-resistant malaria: the role of drug elimination half-life. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[33]  P. G. Shute,et al.  A Study of Induced Malignant Tertian Malaria , 1932, Proceedings of the Royal Society of Medicine.

[34]  P. Rathod,et al.  Variations in frequencies of drug resistance in Plasmodium falciparum. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Rosenberg,et al.  An estimation of the number of malaria sporozoites ejected by a feeding mosquito. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  A. Cowman,et al.  Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  W. Peters,et al.  The prevention of antimalarial drug resistance. , 1990, Pharmacology & therapeutics.

[38]  P. Bloland,et al.  Combination therapy for malaria in Africa: hype or hope? , 2000, Bulletin of the World Health Organization.

[39]  N. White,et al.  Antimalarial pharmacokinetics and treatment regimens. , 1992, British journal of clinical pharmacology.

[40]  P. Newton,et al.  A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. , 2003, Molecular biology and evolution.

[41]  V. Yu,et al.  Antimicrobial Therapy and Vaccines , 1999 .

[42]  Thomas Lavstsen,et al.  Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A‐adhering Plasmodium falciparum involved in pregnancy‐associated malaria , 2003, Molecular microbiology.

[43]  A. Cowman,et al.  Chemotherapy and drug resistance in malaria. , 1990, International journal for parasitology.

[44]  François Nosten,et al.  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number , 2004, The Lancet.

[45]  T. Triglia,et al.  Amplification of the multidrug resistance gene pfmdr1 in Plasmodium falciparum has arisen as multiple independent events , 1991, Molecular and cellular biology.

[46]  C. Curtis,et al.  A simple model of the build-up of resistance to mixtures of anti-malarial drugs. , 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[47]  E. Lagarde,et al.  Impact of chloroquine resistance on malaria mortality. , 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[48]  B. Sharp,et al.  Antifolate antimalarial resistance in southeast Africa: a population-based analysis , 2003, The Lancet.

[49]  N. Fairley,et al.  Sidelights on malaria in man obtained by subinoculation experiments. , 1947, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[50]  C. Plowe,et al.  More on 'the efficacy of antifolate antimalarial combinations in Africa'. , 1999, Parasitology today.

[51]  R. Anderson,et al.  Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[52]  S. Lindsay,et al.  Short-range attractiveness of pregnant women to Anopheles gambiae mosquitoes. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[53]  M. Lemnge,et al.  Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. , 2003, The American journal of tropical medicine and hygiene.

[54]  K. Kirk,et al.  Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum , 2000, Nature.

[55]  C. Plowe,et al.  Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. , 2002, The Journal of infectious diseases.

[56]  J. Beier,et al.  Treatment failure of pyrimethamine‐sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya , 2003, Tropical medicine & international health : TM & IH.

[57]  N. White,et al.  Antimalarial drug resistance and combination chemotherapy. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[58]  W. Peters Drug resistance in malaria--a perspective. , 1969, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[59]  C. Plowe Monitoring antimalarial drug resistance: making the most of the tools at hand , 2003, Journal of Experimental Biology.

[60]  U. d’Alessandro,et al.  Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. , 2000, Parasitology today.

[61]  Geneva,et al.  ANTIMALARIAL DRUG COMBINATION THERAPY Report of a WHO Technical Consultation , 2022 .

[62]  R. Snow,et al.  Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. , 2003, The Lancet. Infectious diseases.